長期開存を目指したヒト冠動脈バイパス血管のセロトニン反応性に関する薬理学的研究

書誌事項

タイトル別名
  • Pharmacological Studies on Responsiveness of 5-Hydroxytryptamine to Overcome Perioperative Spasm of Coronary Artery Bypass Graft
  • チョウキ カイゾン オ メザシタ ヒト カンドウミャク バイパス ケッカン ノ セロトニン ハンノウセイ ニ カンスル ヤクリガクテキ ケンキュウ

この論文をさがす

抄録

  In ischemic heart diseases, the use of the internal thoracic artery (ITA) as an arterial graft has been associated with longer survival and better quality of life. However, it has been reported that vasospasm of the ITA graft frequently occurs and increases perioperative and postoperative morbidity. Serotonin (5-HT) plays an important role in the occurrence of vasospasm. We examined 5-HT receptor subtypes responsible for the 5-HT-induced vasocontraction in the human ITA. The contractile response caused by 5-HT was mediated by activation of not only 5-HT2A receptors but also 5-HT1B receptors. We also examined the relationship between 5-HT-induced vasocontraction of the rabbit femoral artery and arteriosclerosis using the arteriosclerosis model of repeated balloon-injury. The contractile response caused by 5-HT in the femoral artery with arteriosclerosis was significantly greater than that in the normal artery. Additionally, we demonstrated that insulin induced internalization of 5-HT2A receptors from the plasma membrane in HEK293 cells. Diabetes mellitus (DM) is a risk factor for ischemic heart diseases. We evaluated the 5-HT-induced vasocontraction, mediated by activation of 5-HT2A and 5-HT1B receptors, in the ITA obtained from patients with DM or without DM undergoing coronary bypass surgery. The contractile response caused by 5-HT in the ITA from patients with DM was significantly greater than that from patients without DM. Our findings suggest that when the ITA is used as an arterial graft, simultaneous treatment with 5-HT2A and 5-HT1B receptor antagonists is useful to prevent 5-HT-induced vasospasm, especially in patients with DM.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 129 (9), 1049-1053, 2009-09-01

    公益社団法人 日本薬学会

参考文献 (20)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ